Skip to main content
Top
Published in: Hepatology International 5/2023

Open Access 06-04-2023 | Esophageal Varices | Original Article

Endoscopic band ligation is safe despite low platelet count and high INR

Authors: Nikolaus Pfisterer, Michael Schwarz, Mathias Jachs, Florian Putre, Lukas Ritt, Mattias Mandorfer, Christian Madl, Michael Trauner, Thomas Reiberger

Published in: Hepatology International | Issue 5/2023

Login to get access

Abstract

Background

Prophylactic endoscopic band ligation (EBL) is used to prevent variceal bleeding in patients with liver cirrhosis. The association of thrombocytopenia, high INR (international normalized ratio) and liver dysfunction with the risk of procedure-related bleeding (PRB) remains debated and recommendations are controversial.

Methods

We analyzed real-life data of cirrhotic patients undergoing elective EBL at two large Viennese centers between Q1/2000–Q1/2018. PRB was defined as bleeding occurring within 30 days after EBL.

Results

We included 617 patients undergoing a total of 1178 prophylactic EBL procedures (median 2 per patient). Sixteen (2.6%) of 617 patients experienced PRB after a median of 12.5 (IQR 17.3) days with no difference in characteristics and laboratory values between the two groups. The proportion of patients with platelets (PLT) < 50 G/L or INR ≥ 1.5 was similar in patients with vs. without PRB. A higher MELD showed a non-significant association with EBL-related bleeding risk (odds ratio, OR 1.07; 95% confidence interval 95% CI 1.00–1.16, p = 0.058). While serum bilirubin was a significant predictor for PRB (OR: 1.10; 95% CI 1.03–1.18), the presence of large varices (OR 0.85 vs. small varices; 95% CI 0.20–3.84), INR (OR 0.50; 95% CI 0.10–3.14), PLT (OR 1.00; 95% CI 1.00–1.01) and the use of non-selective betablockers (OR 1.20; CI 95% 0.38–3.76) were not associated with PRB.

Conclusion

EBL is safe and procedure-related bleedings are rare (2.6%) including in patients with thrombocytopenia < 50 G/L or high INR ≥ 1.5. Only high MELD, and especially high bilirubin seem to be linked to an increased risk of EBL-related bleeding.
Literature
1.
go back to reference Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412–19.e3CrossRefPubMed Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412–19.e3CrossRefPubMed
2.
go back to reference Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969–2002. Hepatology [Internet]. 2006 ;43:500–5. http://doi.wiley.com/https://doi.org/10.1002/hep.21089. Cited 14 Jan 2020 Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969–2002. Hepatology [Internet]. 2006 ;43:500–5. http://​doi.​wiley.​com/​https://​doi.​org/​10.​1002/​hep.​21089. Cited 14 Jan 2020
4.
go back to reference D’Amico G, de Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology [Internet]. 2003 ;38:599–612. http://doi.wiley.com/https://doi.org/10.1053/jhep.2003.50385. Cited 6 Nov 2017 D’Amico G, de Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology [Internet]. 2003 ;38:599–612. http://​doi.​wiley.​com/​https://​doi.​org/​10.​1053/​jhep.​2003.​50385. Cited 6 Nov 2017
7.
go back to reference Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr [Internet]. 2017;129:135–158. Available from: http://link.springer.com/https://doi.org/10.1007/s00508-017-1262-3. Cited 6 Nov 2017 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr [Internet]. 2017;129:135–158. Available from: http://​link.​springer.​com/​https://​doi.​org/​10.​1007/​s00508-017-1262-3. Cited 6 Nov 2017
8.
go back to reference Garcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology [Internet]. 2017;65:310–335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27786365. Cited 16 Feb 2020 Garcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology [Internet]. 2017;65:310–335. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27786365. Cited 16 Feb 2020
9.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974CrossRefPubMed
11.
12.
go back to reference Pfisterer N, Dexheimer C, Fuchs E-M, Bucsics T, Schwabl P, Mandorfer M, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther [Internet]. 2018;47:966–979. http://www.ncbi.nlm.nih.gov/pubmed/29388229. Cited 16 Jan 2020 Pfisterer N, Dexheimer C, Fuchs E-M, Bucsics T, Schwabl P, Mandorfer M, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther [Internet]. 2018;47:966–979. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29388229. Cited 16 Jan 2020
13.
go back to reference Funakoshi N, Duny Y, Valats JC, Ségalas-Largey F, Flori N, Bismuth M, et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol. 2012;11:369–383CrossRefPubMed Funakoshi N, Duny Y, Valats JC, Ségalas-Largey F, Flori N, Bismuth M, et al. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol. 2012;11:369–383CrossRefPubMed
17.
go back to reference Pfisterer N, Riedl F, Pachofszky T, Gschwantler M, König K, Schuster B, et al. Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding—a national multicentre study. Liver Int [Internet]. 2019;39:290–298. http://www.ncbi.nlm.nih.gov/pubmed/30248224. Cited 2 Aug 2020 Pfisterer N, Riedl F, Pachofszky T, Gschwantler M, König K, Schuster B, et al. Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding—a national multicentre study. Liver Int [Internet]. 2019;39:290–298. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​30248224. Cited 2 Aug 2020
22.
go back to reference Sinclair M, Vaughan R, Angus PW, Gow PJ, Parker F, Hey P, et al. Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. Eur J Gastroenterol Hepatol [Internet]. 2015;27:928–32. http://www.ncbi.nlm.nih.gov/pubmed/25951490. Cited 27 Jul 2020 Sinclair M, Vaughan R, Angus PW, Gow PJ, Parker F, Hey P, et al. Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. Eur J Gastroenterol Hepatol [Internet]. 2015;27:928–32. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25951490. Cited 27 Jul 2020
31.
go back to reference Dueñas E, Cachero A, Amador A, Rota R, Salord S, Gornals J, et al. Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis. Dig Liver Dis. 2020;52:79–83CrossRefPubMed Dueñas E, Cachero A, Amador A, Rota R, Salord S, Gornals J, et al. Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis. Dig Liver Dis. 2020;52:79–83CrossRefPubMed
32.
go back to reference Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology [Internet]. 2017;65:310–335. http://doi.wiley.com/https://doi.org/10.1002/hep.28906.Cited 15 Jan 2018 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology [Internet]. 2017;65:310–335. http://​doi.​wiley.​com/​https://​doi.​org/​10.​1002/​hep.​28906.​Cited 15 Jan 2018
37.
39.
Metadata
Title
Endoscopic band ligation is safe despite low platelet count and high INR
Authors
Nikolaus Pfisterer
Michael Schwarz
Mathias Jachs
Florian Putre
Lukas Ritt
Mattias Mandorfer
Christian Madl
Michael Trauner
Thomas Reiberger
Publication date
06-04-2023
Publisher
Springer India
Published in
Hepatology International / Issue 5/2023
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10515-y

Other articles of this Issue 5/2023

Hepatology International 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.